Skip to main content

Table 2 Diagnostic procedures used for staging, according to primary site (absolute number performed and % positive yield)

From: Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients

Diagnostic Procedure

Head &Necka

Bronchial

GEP

Pheochromocytoma

Unknown Primary

Total

N = 44

N = 16

N = 156

N = 6

N = 24

N = 246

(18) F-FDG PET/CT

6 (100.0)

1 (100.0)

3 (66.7)

0 (0.0)

1 (0.0)

11 (81.8)

Magnetic Resonance

12 (81.8)

4 (100.0)

52 (69.2)

3 (100.0)

14 (78.6)

85 (75.0)

Endoscopic Ultrasound

1 (0.0)

0 (0.0)

21 (81.0)

0 (0.0)

5 (60.0)

27 (74.1)

Bronchoscopy

0 (0.0)

7 (100.0)

0 (0.0)

0 (0.0)

3 (0.0)

10 (70.0)

MIBG

1 (0.0)

0 (0.0)

1 (100.0)

5 (80.0)

3 (33.3)

10 (60.0)

Enteroclysis

0 (0.0)

0 (0.0)

4 (75.0)

0 (0.0)

1 (0.0)

5 (60.0)

Computed Tomography

33 (78.8)

16 (93.8)

126 (43.2)

4 (100.0)

23 (81.8)

202 (58.5)

Abdominal Ultrasound

5 (0.0)

3 (33.3)

65 (50.8)

4 (100.0)

13 (92.3)

90 (55.6)

Gastroscopy

4 (0.0)

3 (0.0)

105 (60.0)

0 (0.0)

14 (14.3)

126 (51.6)

Octreoscan

16 (68.8)

11 (54.5)

107 (44.9)

2 (50.0)

20 (65.0)

156 (50.6)

Colonoscopy

2 (0.0)

2 (0.0)

71 (38.0)

0 (0.0)

15 (0.0)

90 (30.0)

Bone Scan

22 (18.2)

12 (25.0)

10 (22.2)

4 (25.0)

11 (18.2)

59 (20.7)

Endoscopic Capsule

0 (0.0)

0 (0.0)

10 (30.0)

0 (0.0)

6 (0.0)

16 (18.8)

x-Ray

33 (0.0)

15 (100.0)

85 (2.4)

2 (0.0)

17 (17.6)

152 (13.2)

  1. 2-deoxy-2-(18F) fluoro-D-glucose: positron emission tomography/computed tomography (18F-FDG PET/CT), n: number of patients
  2. aincludes 41 MTC and 3 paragangliomas